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Abstract 
Defining chronic kidney disease (CKD) is the subject of intense debate in the current nephrology literature. The debate concerns 
the threshold value of estimated glomerular filtration rate (eGFR) used to make the diagnosis of CKD. Current recommendations 
argue that a universal threshold of 60 mL/min/1.73m² should be used. This threshold has been defended by epidemiological 
studies showing that the risk of mortality or end-stage renal disease increases with an eGFR below 60 mL/min/1.73m². However, 
a universal threshold does not take into account the physiologic decline in GFR with ageing nor does it account for the risk of 
mortality and end-stage renal disease being trivial with isolated eGFR levels just below 60 mL/min/1.73m² in older subjects 
and significantly increased with eGFR levels just above 60 mL/min/1.73m² among younger patients. Overestimation of the 
CKD prevalence in the elderly (medicalisation of senescence) and underestimation of CKD (potentially from treatable primary 
nephrologic diseases) in younger patients is of primary concern. An age-calibrated definition of CKD has been proposed to 
distinguish age-related from disease-related changes in eGFR. For patients younger than 40 years, CKD is defined by eGFR 
below 75 mL/min/1.73m². For patients with ages between 40 and 65 years, CKD is defined by 60 mL/min/1.73m². For subjects 
older than 65 years without albuminuria or proteinuria, CKD is defined by eGFR below 45 mL/min/1.73m².
Introduction: what is the controversy?
Chronic kidney disease (CKD) is often described as the 
“silent killer” in medicine, as this pathology is seldom 
symptomatic until the glomerular filtration rate (GFR) is 
severely decreased. Therefore, blood and urine screening 
during routine medical care is of key importance. The two 
most useful biomarkers to assess the kidney health are GFR 
and albuminuria (or proteinuria) assessment.1 Other more 
specific tests exist for characterising CKD but are beyond 
the scope of this review article. Estimation of GFR (eGFR) 
is based on renally-filtered serological biomarkers, most 
commonly serum creatinine levels (SCr)-based equations.2 
The value of SCr is dependent on GFR but also on muscular 
mass, tubular secretion of creatinine and to some extent 
dietary consumption of lean, cooked meat. Moreover, the 
relationship between SCr and GFR is a reciprocal function. 
Estimation of GFR by creatinine-based equations includes 
other variables like gender, ethnicity and, importantly for our 
discussion, age.3,4 There have been multiple creatinine-based 
equations developed3,5,6 as well as methods of albuminuria or 
proteinuria testing developed.7-10 To simplify the discussion, 
we will consider the recommendations of the widely 
disseminated Kidney Disease Improving Global Outcome 
(KDIGO) guidelines.1 They recommend the Chronic Kidney 
Disease Epidemiology (CKD-EPI) equation and the urinary 
albumin (or protein)-creatinine ratio (UACR) on a random 
spot urine sample, preferably obtained in the morning. 
Based on these two parameters, the KDIGO have defined 
classification or categorisation for CKD (Table 1).1 Basically, 
the subject or the patient can be classified in 6 different 
categories according to the eGFR level: from category 1 when 
the eGFR is over 90 mL/min/1.73m² to category 5 when eGFR 
is below 15 mL/min/1.73m², the category 3 being divided into 
3A (eGFR between 45 and 59 mL/min/1.73m²) and 3B (eGFR 
between 30 and 44 mL/min/1.73m²).1,11 It is fundamental to 
understand that the label of “CKD” will be attributed to every 
patient with an eGFR below 60 mL/min/1.73m², even in the 
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absence of abnormal albuminuria, whereas the diagnosis will 
be considered in patients with eGFR over 60 mL/min/1.73m², 
only if they have one additional evidence of kidney injury, 
most of the time, abnormal UACR. Also of importance, eGFR 
below 60 mL/min/1.73m² must persist for at least 3 months 
to be considered CKD.1 Absent from the KDIGO definition 
of CKD is any consideration for the age-related decline in 
GFR. Many physiological functions naturally decrease with 
ageing.12-19 Failure to account for this in the definition of CKD 
has led to many elderly subjects being misclassified as having 
CKD, even when their modest reduction in eGFR is the 
normal expected change in physiology with ageing.12,13,15,18,20-25 
We proposed an alternative classification in subjects older 
than 65 years where category 3A will not be considered as 
CKD in the absence of any other sign of kidney damage (like 
an abnormal UACR).23 Moreover, we also proposed the GFR 
threshold of CKD for patients younger than 40 years be raised 
at 75 mL/min/1.73m².26 Thus, the definition of CKD by eGFR 
thresholds alone should be age-calibrated in order to identify 
pathological reductions in GFR that do not simply occur with 
normal ageing.
What is the definition of normality in diagnostic medicine?
While perhaps thought to be easily determined, clinical 
chemists are well aware that determining “normal reference 
ranges” can be quite challenging.27,28 Establishing normal 
reference values is however of much importance as they will 
often be used to define a disease status. Basically, there are 
two main methods to define normality in medicine:12 1) the 
classical method measures the parameter in a presumably 
healthy, normal, representative population and calculate a 
range value such as the 2.5th to 97.5th percentiles; 2) the risk-
based method considers the risk of outcomes associated with 
the thresholds. The first method is applied for most parameters 
in clinical chemistry. For example, the normal values of a 
parameter like parathyroid hormone will be very different if 
global healthy subjects are considered (like blood donors) or 
if the definition of normality is more restrictive and requires 
subjects with normal eGFR, calcium and vitamin D levels.29 
An example of the risk-based method is the serum cholesterol 
concentration for which clinically relevant thresholds are 
determined according to risk of cardiovascular events as 
well as established clinical benefit with treatment to these 
thresholds.30 Perhaps ideally, both methods would give more 
or less the same reference limits of “normal” GFR.
Normal GFR range: the classical method
Normal GFR values observed in young healthy adult 
populations are approximately 100-110 mL/min/1.73m², even 
if results can vary slightly depending on the method used to 
Table 1. GFR categories according to the KDIGO.1 Category 
1 and 2 are CKD only if additional kidney injury. Our proposal 
is that category 3A is no longer considered as CKD in subjects 









Figure 1. Percentile (P) values (97.5th, 50th and 2.5th) for 
estimated GFR (eGFR; in mL/min/1.73m2) by the CKD-EPI 
equation for healthy community living (Caucasian) adult 
Males and Females according to age between 18 and 85+ 
years (adapted with permission from van den Brand et al, 
201132) . For comparison, the KDIGO threshold for defining 
CKD is given as a bold horizontal line (60 mL/min/1.73m2). 
Note the substantial numbers of individuals >60 years of age 
in the 2.5th to approximately the 40th percentile of eGFR that 
fall below the 60mL/min/1.73m2 threshold.
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measure GFR (mGFR) (e.g. with reference methods using 
inulin, iothalamate, 51Cr-EDTA or iohexol)12,17,18 or estimated 
GFR.31,32 It is obvious from these studies involving healthy 
populations that GFR decreases with ageing. This decrease 
in GFR is confirmed either with mGFR (including living 
kidney donors) 12,17,18 or eGFR (including healthy general 
population).31,32 This ageing process is illustrated in Figure 
1. From these studies, it can be concluded that a significant 
part of the healthy population older than 65 years of age have 
a GFR (mGFR or eGFR) below 60 mL/min/1.73m². These 
results are clear and strong arguments for the necessity of an 
age-calibrated CKD categorisation.
Normal GFR range: the prognostic method
The unique threshold of 60 mL/min/1.73m² for CKD 
definition by the KDIGO is justified by a risk based approach.1 
The arguments mainly come from the CKD-EPI prognosis 
consortium epidemiologic studies.33-36 These investigators 
have collected data from several large cohorts of patients 
worldwide. The sample sizes (over 1 million subjects) are 
very impressive but the methodology used to determine 
eGFR is more questionable. Among other methodological 
criticisms, we underline the absence of IDMS (isotope 
dilution mass spectrometry) traceable standardised creatinine 
assay in several cohorts,37 and the fact that these studies lack 
confirmation of decreased eGFR for at least 3 months.38 A 
recent study with a follow-up of 25 years in 3888 Icelandic 
people showed that the risk of CKD 20 years hence for a 
woman who is currently aged 45 years, will decrease from 
16.8 to 8.6%, if CKD is changed from one eGFR value below 
60 mL/min/1.73m² to two consecutive values below 60 mL/
min/1.73m² over 3 months.39 Lack of confirmation of eGFR 
in epidemiological “one-off” studies leads to a large number 
of “false-positive” results. Studies by the CKD-EPI prognosis 
consortium also demonstrate a significant higher risk of death 
when eGFR is below 60 mL/min/1.73m². Further, the risk of 
mortality associated with an eGFR below 60 mL/min/1.73m² 
remains statistically significant at any age, albeit the relative 
risk was substantially attenuated in older adults.34 
Is the debate on age-calibration of thresholds of eGFR for 
defining CKD relevant?
Before going further into the details of the debate on the 
wisdom of an age-calibrated CKD definition, it seems 
important to know if the changes proposed are relevant, and 
not purely semantic. In other words, it should be shown that an 
age-calibration proposal has an impact on the epidemiology 
of CKD in the general population. A proposal that subjects 
classified in stage 3A without UACR do not have CKD would 
greatly impact the prevalence of CKD.23 In Figure 2, one can 
observe the prevalence of CKD in the United States according 
to the KDIGO definition based on eGFR and UACR. The 
global prevalence is as high as 11.5%. If we focus only on the 
subset of patients considered to have CKD by eGFR below 
60 mL/min/1.73m² but without albuminuria, the prevalence 
is 4.8%. Also, the prevalence of subjects classified in CKD 
category 3A and without albuminuria (CKD 3A1), is 3.6%.1 
This CKD category 3A1 is clearly the most important from an 
epidemiological point of view and corresponds to millions of 
subjects in the US. A study in Italy confirmed that CKD 3A is 
the most important contributor to the CKD epidemiology.40,41 
Moreover, Figure 3 illustrates that the proportion of CKD 
diagnosis based on “eGFR only” increases with ageing.42 
In other words, in young patients, the vast majority of CKD 
patients will have increased UACR and “normal” eGFR (at 
least according to the KDIGO criteria) whereas among older 
subjects, most will be labelled as CKD because of an eGFR 
just below 60 mL/min/1.73m², but with a normal UACR. 
Clearly, the proposal that older subjects classified in CKD 3A1 
Figure 2. Prevalence of CKD in USA based on ACR and 
eGFR with the KDIGO classification system. Reprinted with 
permission from KDIGO.1
Figure 3. Proportion of CKD based on eGFR (yellow), ACR 
(green) or both (red) in different age categories (adapted from 
reference 42).
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do not actually have CKD is very relevant to the prevalence of 
CKD. In particular, the alarmingly high prevalence of CKD in 
the elderly (as high as 50%) with the current KDIGO based 
definition will be greatly decreased with adoption of an age-
calibrated system.21,39,43,44
Is the definition of normality based on risk prediction 
misleading and potentially confusing?
Use of the prognostic (risk-based) method for CKD definition 
may be defendable with albuminuria,8,11 but such a strategy 
is much more questionable for eGFR. The reasons are 
several. Firstly, there exists a large disagreement concerning 
the level of eGFR associated with increased mortality, i.e. 
60 mL/min/1.73m² and eGFR actually observed in healthy 
populations.12,22 For example, in the healthy population 
described by van den Brand et al in the Netherlands, low 
normal eGFR value (defined as the 5th percentile) is 94 and 85 
mL/min/1.73m² at 25-29 years, 67 and 70 mL/min/1.73m² at 
50-54 years and 44 and 51 mL/min/1.73m² at 70-74 years, for 
men and women respectively.32 Secondly, the prognosis-based 
threshold could be different according to the chronicity of 
the reduced eGFR.22 For example, an earlier study to suggest 
that increased all-cause mortality risk was independently 
associated with decreased eGFR was published in 2004 by 
Go et al. The authors showed that patients with eGFR of 45-
59 mL/min/1.73m² had a higher risk of all-cause mortality 
compared to an eGFR of 60ml/min/1.73m² or greater. 
However, this increased risk disappeared completely when a 
subgroup of subjects with repeated measurement of eGFR was 
considered.45 Thirdly, the prognostic approach could lead to 
different CKD definitions if other GFR biomarkers, like serum 
cystatin C, were used to estimate GFR. Indeed, the threshold 
for worse prognosis would move the diagnosis of CKD from 60 
to 80 mL/min/1.73m² with cystatin C-based equation,22,46 even 
if we question if cystatin C-based equations really give better 
estimates of GFR,47 and if better association with mortality 
is not due to non-GFR determinants of cystatin C, such as 
obesity or inflammation.48 Finally, age, a strong predictor of 
mortality, is also an important variable in all eGFR estimating 
equations and could thus inflate all these associations.19,22,49
Is the risk of mortality associated with GFR really the 
same with ageing?
The concept that a unique threshold of 60 mL/min/1.73m² 
is associated with risk of mortality whatever the age is also 
questionable. A careful study of findings by the CKD-EPI 
consortium is helpful.34 Firstly, contrary to the interpretations 
by the authors, these data support an age-calibration to CKD 
classification for the purposes of mortality risk. Secondly, 
other studies with discordant results compared to those of this 
study34 support the argument for an age-calibrated definition 
of CKD based on a mortality risk formulation (see below 
“Data from other CKD cohorts”).
Data from the CKD-EPI prognosis consortium
In the first CKD-EPI prognosis consortium study, not age-
calibrated, the reference value of eGFR used for the hazard 
ratio (HR) calculation was 95 mL/min/1.73m².36 In other 
words, the significant higher risk of eGFR below 60 mL/
min/1.73m² is calculated in comparison with an eGFR of 95 
mL/min/1.73m². This value makes sense as it is comparable 
to normal eGFR values observed in a young adult healthy 
population. In 2012, the same consortium looked again at 
the risk of mortality across categories of age.34 However, the 
Figure 4. HR for mortality when the reference group19 is the 
one with the lowest risk. eGFR ranges into the brackets (low 
risk) are not significantly different from the reference group.
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reference value of eGFR for risk calculations was 80 mL/
min/1.73m², not 95 mL/min/1.73m². This was done because 
there were not enough older individuals with higher eGFR to 
use as a reference group. This implicitly accepts that: 1) that 
the “normal” GFR decreases with ageing, and 2) the eGFR 
reference group for HR calculations can change according to 
age. However, one can easily recalculate the HR with different 
reference groups. Indeed, it seems fully logical to choose as 
reference group, the eGFR range which is actually associated 
with the lowest risk (Figure 4). Considering this strategy, one 
can easily conclude that:1) with ageing, the eGFR range of 
the reference group decreases, which is expected regarding 
the natural decline of GFR with ageing; 2) in subjects older 
than 65 years, CKD category 3A1 (eGFR of 45 to 59 mL/
min/1.73m²) is associated with a trivial risk of mortality, 
whereas eGFR below 75 mL/min/1.73m² is associated with a 
notably increased mortality in the youngest adult age group.19 
Thus, an age-calibrated reference group applied to published 
data34 supports an age-dependent definition of CKD if based 
on mortality risk. 
Data from other CKD cohorts
Besides the CKD-EPI prognosis consortium, other 
epidemiological data suggested that risk of mortality in elderly 
with eGFR just below 60 mL/min/1.73m² could be even more 
trivial or non-existent. Roderick et al analysed data from a 
UK cohort of people 75 years and older with a median follow-
up of 7.3 years. They demonstrated that the mortality risk 
was significantly higher only when eGFR was below 45 mL/
min/1.73m², but not if eGFR was 45-59 mL/min/1.73m².50 In 
US, O’Hare analysed a large database of the Veteran Affairs 
(n=2,583,911) and showed that eGFR predicted the risk of 
mortality in the eGFR range of 50-59 mL/min/1.73m², only 
in patients younger than 65 years.51 Data from the REGARDS 
study (for “REasons for Geographic and Racial Differences in 
Stroke”) confirmed that patients older than 70 years with an 
eGFR between 45 and 59 mL/min/1.73m² have no increased 
significant risk of mortality if the UACR was normal.52 In 
France, the Three-City Study confirmed that eGFR was 
associated with mortality but the threshold was near to 45 
mL/min/1.73m² in this cohort with a mean age of 74 years.53 
Comparable results are observed in an Italian population with 
mean age of 71 years where CKD category 3B but not 3A 
was associated with higher mortality on a median follow-
up of 7.2 years.41 A large Canadian database (n=949,119) 
confirmed that life expectancy was similar in the elderly if 
category CKD 3A or category CKD 1-2 was considered.54 
In a very recent study from Sweden, authors followed eGFR 
in 363 elderly women for 10 years between ages 75 and 85 
years. They also found that category CKD 3B, but not 3A, 
was associated with mortality in 1011 women considered 
at baseline.55 This last study must however be interpreted 
carefully as no UACR measurements were available and a 
lack of statistical power is possible. The absence of UACR 
measurements is unfortunately a frequent limitation of several 
epidemiological studies on this topic.39,55-59 Many other 
epidemiological reports utilising large cohorts have included 
values for both eGFR and UACR, but the subjects with CKD 
category 3A without abnormal UACR have not commonly 
been specifically examined.60,61 
What about the risk of end stage renal disease (ESRD)?
Many studies have shown that the risk of ESRD increases 
with lower eGFR, even well above the 60 mL/min/1.73m² 
threshold. There are also several reasons why an age-calibrated 
approach is logical with eGFR thresholds for purposes of 
ESRD risk. First, with ageing, there is an important competing 
risk between mortality and ESRD. Indeed, with ageing, the 
risk of dying increases and exceeds the risk of ESRD.51,62,63 
Notably, we can only say these elderly patients with category 
3A CKD (eGFR 45 to 59 mL/min/1.73m²) die with CKD, as 
evidence that modest age-related reduction in GFR plays a 
causal role in mortality lacks any good evidence. Second, 
risk models used for predicting ESRD show that older age is 
associated with a lower risk of ESRD compared to a younger 
patient with the same eGFR.64 Indeed, the risk of ESRD in 
a 75 year old male with an eGFR of 50 mL/min/1.72 m², no 
albuminuria, and otherwise unremarkable biochemistry is 
only 0.2% at 5 years. Thus, it is difficult to justify a label of 
CKD based on ESRD risk for elderly patients with category 
3A CKD without albuminuria.
The “below 60 mL/min/1.73m²” threshold leads to under-
diagnosis of CKD in young adults 
We have focused our critique of CKD definition based on 
eGFR below 60 mL/min/1.73m² to the elderly because 
these people represent the majority of the so-called “CKD 
epidemic” and are misdiagnosed with a disease that is simply 
normal ageing. Even considering true CKD in elderly people, 
i.e. category CKD 3B or higher and/or positive ACR, the 
vast majority of CKD in elderly is related to hypertension 
and/or diabetes.65 Primary nephrologic diseases, including 
glomerulonephritis, can be diagnosed without even needing 
eGFR in young patients even if their prevalence is very low.66 
Such a diagnosis is of prime importance as specific effective 
therapies are available for glomerulonephritis. Of course, 
albuminuria and proteinuria measurements are a key tool for 
diagnosing such diseases. But regarding the eGFR criteria, 
the threshold of 60 mL/min/1.73m² can be considered as 
much too low for young people, where a normal GFR is closer 
to 100-110 mL/min/1.73m². Strictly speaking, these young 
patients could lose many nephrons, seeing their GFR value 
decreasing near to half, before being categorised as CKD.26 
In summary, we consider that the current CKD classification 
overestimates the prevalence of CKD in older patients with 
very frequent but secondary (“secondary” meaning that 
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another disease such as hypertension or diabetes precedes the 
CKD) nephrologic diseases but underestimates the prevalence 
of CKD in younger patients with rare but primary nephrologic 
diseases that are potentially treatable.
The gold standard tool for CKD classification
Because the definition of CKD based on mortality risk alone 
lacks evidentiary support, one must return to the classical 
method to define normality and study normal healthy 
populations to define reference limits for GFR. The main issue 
with GFR is the physiological decline of GFR with ageing. The 
best scientific tool to define the lower reference limit would be 
the use of percentiles such as the 5th or 2.5th percentile (Figure 
1).21,67 Such an approach would avoid both false negative (in 
young people) and false positive (in elderly individuals) in 
the diagnosis of CKD. Such data are available in the literature 
for eGFR both in Caucasians and Asians.31,32,67,68 For mGFR, 
several publications are available in all ethnicities though 
we need more data for subjects older than 70 years.17,18,69 
Percentiles of values for eGFR according to age (see Figure 
1) to create entirely new age-calibrated eGFR thresholds for 
all categories of CKD 1 to 5 are thus attractive, but perhaps 
too complicated and challenging to implement in view of the 
worldwide acceptance of the current categorisation and its 
laboratory reporting. A simpler approach would be to use age-
calibrated eGFR thresholds for defining CKD rather than for 
all categories of CKD. If a laboratory is capable of calculating 
eGFR, then it should be capable of calculating the eGFR 
threshold for that age (by simply filling in the 95th or 97.5th 
percentile for serum creatinine) and comparing both values. 
This change would however call upon worldwide laboratory 
implementation and reporting. Moreover, the choice of the 
most useful lowest percentile (5th, 2.5th or 3th) still needs to 
be defined. Our proposal to consider category CKD 3A1 
(without any kidney damage) as non-CKD for subjects older 
than 65 years and an eGFR below 75 mL/min/1.73m² as CKD 
in patients younger than 40 years seems a good compromise 
that would be simpler.23,26
Are these proposals nihilist and arbitrary?
The age-calibrated categorisation for identification of 
legitimate CKD is not unique in medicine. For example, 
pulmonologists recognise organ senescence in their specialty 
and its impact on lung function.70 The forced expiratory 
volume in 1 second (FEV1) is the functional equivalent of 
GFR for the lung and is interpreted with age-specific reference 
ranges to account for its gradual decline with ageing. An 
older individual with an isolated age-related reduction of 
FEV1 is not labeled as suffering from chronic lung disease. In 
addition, the latest iteration of the Joint National Commission 
on Hypertension (JNC-8) also recognises the need for age-
stratification of thresholds of blood pressure when making 
treatment decisions.71 By a same logical reasoning, a lower 
eGFR (or mGFR) in older subjects need not be ascribed 
exclusively to a “disease”, but can be regarded as within 
the spectrum of physiological ageing and its associated 
anatomical and functional consequences.13-15,19
Three main arguments are frequently put forward against this 
age-calibrated categorisation for CKD. Firstly, the proposal 
does not fully recognise the risk inherent to progressively 
declining GFR and thereby may discourage future research 
in the field of nephrology, especially in geriatric nephrology.72 
Secondly, the proposal does not take into account the potential 
risk both of acute kidney injury and/or potential toxicity 
due to the lack of drug dosage adjustment of water-soluble 
therapies in CKD.73 Thirdly, the new thresholds for young and 
old people are arbitrary and may lead to a “birthday” paradox 
where diagnoses would change in individuals based on an 
older age alone even in the presence of unchanging eGFR.
Regarding the first argument, we have discussed the weak 
and inconsistent evidence linking isolated eGFR just below 
60 mL/min/1.73m² to an increased risk of mortality in the 
elderly. Even regarding “true” CKD among older patients, 
it is clear that up to now, the main therapy to fight against 
CKD progression is to treat the underlying cause/risk 
factors for CKD, namely hypertension and/or diabetes.1 
The lack of any specific nephrologic therapies to slow down 
CKD progression is however not an argument per se as it 
is possible such therapies may be developed in the future. 
However, innovative therapies must be studied and tested in 
true CKD patients where the risk is high enough to observe a 
meaningful improvement from new therapies. This point can 
be illustrated ad absurdum: renin-angiotensin system (RAS) 
inhibitors are without doubt the most effective therapies in 
nephrology to prevent ESRD.74 However, a recent simulation 
study with real-life data demonstrated that therapies with 
RAS inhibition would be considered as totally ineffective if 
studies were performed in elderly subjects with category 3A 
CKD and no albuminuria!63 
The second argument considers the possibility that subjects 
at category CKD 3A1 have an increased risk of developing 
an adverse event when prescribed standard doses of water-
soluble, potentially toxic agents. But, there are very few, 
if any, nephrotoxic drugs for which a dose adjustment is 
already recommended at this level of eGFR, 45-59 mL/
min/1.73m².11 Moreover, well-designed prospective studies 
must be performed to validate the hypothesis that such 
labelling in older subjects with an eGFR of 45-59 ml/min and 
no abnormal proteinuria are at greater risk of adverse events 
from pharmacological agents than those of similar age with an 
eGFR over 60 mL/min/1.73m².
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The third argument considers the proposed threshold of 
less than 45 mL/min/1.73m² in the ageing subjects and less 
than 75 mL/min/1.73m² in the young subject as being as 
arbitrary as the 60 mL/min/1.73m² threshold. However these 
thresholds account for the irrefutable decline in GFR with 
age. These thresholds correspond to a clinically significant 
increase in mortality risk (Figure 4). Finally, these thresholds 
are obtained from the serum creatinine distribution of healthy 
subjects in combination with the most appropriate eGFR 
calculation formulas,28,75 CKD-EPI4 and BIS (for “Berlin 
Initiative Study”).76 It is known that the distribution of serum 
creatinine for healthy Caucasians is centred at 0.90 umol/L, 
with 97.5th percentile of 1.20 mg/dL (males) and 0.93 umol/L 
(females).28,75 Assuming a Gaussian distribution and to avoid 
that 2.5% is considered ‘abnormal’; the normal range may 
extend to 1.35 mg/dL for males and 1.05 mg/dL for females, 
corresponding to the 99.9th percentile. By incorporating this 
upper reference limit (99.9th percentile) for serum creatinine 
into the CKD-EPI formula, most suited for that level of GFR, 
we have:  
eGFR = 141 x (1.35/0.90)-1.209 x (0.993)Age = 86.4 x (0.993)Age 
for males 
eGFR = 144 x (1.05/0.70)-1.209 x (0.993)Age = 88.2 x (0.993)Age 
for females,
or eGFR (Lower Limit) ≈ 87.3 x (0.993)Age for both sexes.
The latter formula could be used as an age-dependent cut-off 
formula. If age is between 65 and 100 years, then this age-
dependent cut-off would extend from 55 ml/min/1.73m² at 65 
years to 43 ml/min/1.73m² at 100 years, with a mean of 49 
ml/min/1.73m² for the over 65. A similar approach applied 
to the BIS1 eGFR equation, most suitable for the older age-
group,76 would give a mean for this age group (>65years) of 
45 ml/min/1.73m², the precise cut-off we are advocating to 
define CKD in the over 65 years group. The same reasoning 
is applicable in young subjects and justifies the choice of 75 
mL/min/1.73m².26
Conclusions
Diagnosing and labelling the elderly as having CKD by 
the KDIGO definition is not free of unwanted adverse 
consequences. A diagnosis of CKD can be a substantial source 
of anxiety and stress in the elderly. Moreover, such erroneous 
diagnostic leads to unnecessary referral to nephrologists, and 
potential unnecessary expensive laboratory testing and/or 
imaging. Acquiring such a label of CKD might also interfere 
with obtaining health and life insurance. Finally, such “over-
diagnosing” also has impact on potential screening programs, 
and probably explains, at least in part, why population-based 
CKD screening is actually not very useful and not generally 
recommended.65,77 Why has a non-age-calibrated classification 
system been so widely (and uncritically in our view) been 
adopted? In some countries, reimbursement policies favour the 
identification of CKD, particularly at earlier stages. Finally, 
the widespread application of risk-based CKD definition to 
individuals is an indication of how nephrology is moving 
away from personalised, pathophysiological based diagnosis 
and towards population, epidemiological based “one size fits 
all” medicine. 
In this opinion paper, arguments have been made that support 
a move from a CKD definition based on fixed eGFR threshold 
“below 60 mL/min/1.73m²” to an age-calibrated one. These 
arguments have received positive feedback from clinicians. 
In addition mass media have questioned the current definition, 
based on some of these arguments.78 However, to be fair, it 
must be stated that this call for an age-calibrated definition of 
CKD has still not convinced the leaders of the KDIGO.73 The 
question remains open.
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